These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. In Brief: Endothelial-to-mesenchymal transition. Sanchez-Duffhues G; Orlova V; Ten Dijke P J Pathol; 2016 Feb; 238(3):378-80. PubMed ID: 26446982 [TBL] [Abstract][Full Text] [Related]
4. The Endothelial-mesenchymal Transition in Systemic Sclerosis Is Induced by Endothelin-1 and Transforming Growth Factor-β and May Be Blocked by Macitentan, a Dual Endothelin-1 Receptor Antagonist. Cipriani P; Di Benedetto P; Ruscitti P; Capece D; Zazzeroni F; Liakouli V; Pantano I; Berardicurti O; Carubbi F; Pecetti G; Turricchia S; Alesse E; Iglarz M; Giacomelli R J Rheumatol; 2015 Oct; 42(10):1808-16. PubMed ID: 26276964 [TBL] [Abstract][Full Text] [Related]
5. Transforming growth factor-β-induced endothelial-to-mesenchymal transition is partly mediated by microRNA-21. Kumarswamy R; Volkmann I; Jazbutyte V; Dangwal S; Park DH; Thum T Arterioscler Thromb Vasc Biol; 2012 Feb; 32(2):361-9. PubMed ID: 22095988 [TBL] [Abstract][Full Text] [Related]
6. Endothelial-to-mesenchymal transition and microRNA-21: the game is on again. Cavarretta E; Latronico MV; Condorelli G Arterioscler Thromb Vasc Biol; 2012 Feb; 32(2):165-6. PubMed ID: 22258897 [No Abstract] [Full Text] [Related]
7. Notch signal regulates corneal endothelial-to-mesenchymal transition. Li C; Dong F; Jia Y; Du H; Dong N; Xu Y; Wang S; Wu H; Liu Z; Li W Am J Pathol; 2013 Sep; 183(3):786-95. PubMed ID: 23850080 [TBL] [Abstract][Full Text] [Related]
9. TGF-β-Induced Endothelial-Mesenchymal Transition in Fibrotic Diseases. Pardali E; Sanchez-Duffhues G; Gomez-Puerto MC; Ten Dijke P Int J Mol Sci; 2017 Oct; 18(10):. PubMed ID: 29039786 [TBL] [Abstract][Full Text] [Related]
10. Fibroblast growth factor receptor 1 is a key inhibitor of TGFβ signaling in the endothelium. Chen PY; Qin L; Tellides G; Simons M Sci Signal; 2014 Sep; 7(344):ra90. PubMed ID: 25249657 [TBL] [Abstract][Full Text] [Related]
11. Bosentan and macitentan prevent the endothelial-to-mesenchymal transition (EndoMT) in systemic sclerosis: in vitro study. Corallo C; Cutolo M; Kahaleh B; Pecetti G; Montella A; Chirico C; Soldano S; Nuti R; Giordano N Arthritis Res Ther; 2016 Oct; 18(1):228. PubMed ID: 27716320 [TBL] [Abstract][Full Text] [Related]
12. Endocardial fibroelastosis is caused by aberrant endothelial to mesenchymal transition. Xu X; Friehs I; Zhong Hu T; Melnychenko I; Tampe B; Alnour F; Iascone M; Kalluri R; Zeisberg M; Del Nido PJ; Zeisberg EM Circ Res; 2015 Feb; 116(5):857-66. PubMed ID: 25587097 [TBL] [Abstract][Full Text] [Related]
13. Transforming growth factor beta-induced endothelial-to-mesenchymal transition: a switch to cardiac fibrosis? Goumans MJ; van Zonneveld AJ; ten Dijke P Trends Cardiovasc Med; 2008 Nov; 18(8):293-8. PubMed ID: 19345316 [TBL] [Abstract][Full Text] [Related]
14. Dyssynchronous pacing triggers endothelial-mesenchymal transition through heterogeneity of mechanical stretch in a canine model. Mai J; Hu Q; Xie Y; Su S; Qiu Q; Yuan W; Yang Y; Song E; Chen Y; Wang J Circ J; 2015; 79(1):201-9. PubMed ID: 25373595 [TBL] [Abstract][Full Text] [Related]
15. Angiotensin II activates the Smad pathway during epithelial mesenchymal transdifferentiation. Carvajal G; Rodríguez-Vita J; Rodrigues-Díez R; Sánchez-López E; Rupérez M; Cartier C; Esteban V; Ortiz A; Egido J; Mezzano SA; Ruiz-Ortega M Kidney Int; 2008 Sep; 74(5):585-95. PubMed ID: 18509316 [TBL] [Abstract][Full Text] [Related]
16. Epithin, a target of transforming growth factor-beta signaling, mediates epithelial-mesenchymal transition. Lee HS; Kim C; Kim SB; Kim MG; Park D Biochem Biophys Res Commun; 2010 May; 395(4):553-9. PubMed ID: 20398629 [TBL] [Abstract][Full Text] [Related]